Vaxcyte Analyst Price Targets - Benzinga

Vaxcyte Inc

PCVXNASDAQ

Trade with Public

Trade with Public

$61.16

-0.01-0.02%

At close: Sep 4, 5:00 PM EST

$61.16

N/A

After Hours: Sep 4, 4:00 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Vaxcyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vaxcyte (PCVX).

Price Target Range — 10 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$121Upside to Avg. PT+97.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Feb 26, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$85→$89
Feb 2, 2026	Guggenheim	Seamus Fernandez	Maintained	Buy	$116
Jan 7, 2026	Needham	Joseph Stringer	PT Raise	Buy	$90→$110
Nov 10, 2025	BTIG	Thomas Shrader	Maintained	Buy	$85
Oct 16, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$160→$85
Sep 12, 2025	Goldman Sachs	Asad Haider	Initiate	Neutral	$38
Apr 22, 2025	Cantor Fitzgerald	Carter Gould	Initiate	Overweight	—
Apr 8, 2025	Needham	Joseph Stringer	Maintained	Buy	$90
Apr 1, 2025	Goldman Sachs	Chris Shibutani	PT Cut	Buy	$138→$100
Apr 1, 2025	B of A Securities	Jason Gerberry	PT Cut	Buy	$157→$137
Apr 1, 2025	Needham	Joseph Stringer	PT Cut	Buy	$140→$90
Mar 12, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	$160
Feb 26, 2025	Needham	Joseph Stringer	Maintained	Buy	$140
Feb 24, 2025	BTIG	Thomas Shrader	Maintained	Buy	$160
Feb 11, 2025	Needham	Joseph Stringer	Maintained	Buy	$14
Dec 20, 2024	Goldman Sachs	Chris Shibutani	Initiate	Buy	$135
Nov 6, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Nov 6, 2024	Needham	Joseph Stringer	Maintained	Buy	$140
Sep 10, 2024	Mizuho	Salim Syed	PT Raise	Outperform	$113→$163

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89

BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $85 to $89.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Vaxcyte, Maintains $116 Price Target

Guggenheim analyst Seamus Fernandez reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $116 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Vaxcyte, Raises Price Target to $110

Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $90 to $110.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Vaxcyte, Maintains $85 Price Target

BTIG analyst Thomas Shrader reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $85 price target.

Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Vaxcyte with Neutral Rating, Announces Price Target of $38

Goldman Sachs analyst Asad Haider initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Neutral rating and announces Price Target of $38.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Vaxcyte with Overweight Rating

Cantor Fitzgerald analyst Carter Gould initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Overweight rating.

Benzinga Newsdesk